Baker Bros. Advisors LP filed a Form 4 with the SEC on November 6, 2026, disclosing five open-market purchases of Madrigal Pharmaceuticals, Inc. common stock totaling 91,806 shares acquired between November 4 and November 6, 2026.
Brandon Thomas Harper, Chief Accounting Officer of Mount Logan Capital Inc., filed an initial statement of beneficial ownership with the SEC on November 6, 2026, disclosing direct holdings as of the event date of November 3, 2026.
Jazz Pharmaceuticals plc SVP and Chief Accounting Officer Patricia Carr filed a Form 4 on November 6, 2026, disclosing transactions in ordinary shares on November 4, 2026, including an option exercise and two open-market sales.
Gilead Sciences, Inc. filed a Schedule 13G with the SEC on November 5, 2026, disclosing beneficial ownership of 2,879,996 shares of Aspen Neuroscience, Inc. common stock, representing 9.9% of the class, based on an event date of October 30, 2026.
Addus HomeCare Corporation officer David Tucker filed a Form 144 notice of proposed sale on November 6, 2026, covering 14,850 shares of common stock with an aggregate market value of $1,852,566.40.
Addus HomeCare Corporation officer Cliff Blessing filed a Form 144 notice on November 6, 2026, disclosing a proposed sale of 2,000 shares of Addus HomeCare common stock through Morgan Stanley Smith Barney LLC.
Robert E. Boyle, an officer of Prudential Financial Inc, filed a Form 144 notice of proposed sale of 2,876 shares of common stock on November 6, 2026, through broker Morgan Stanley Smith Barney LLC Securities Executive Services.
Lincoln National Corporation officer Sean Woodroffe filed a Form 144 notice of proposed sale on November 6, 2026, covering 17,500 shares of Lincoln National common stock to be sold through J.P. Morgan Securities LLC on NYSE.
Andreas Bechtolsheim, a 10% stockholder of Arista Networks, Inc., filed a Form 144 notice of proposed sale of 260,000 shares of common stock, with an approximate sale date of November 6, 2026, through Goldman Sachs & Co. LLC on the NYSE.
CRISPR Therapeutics AG officer Raju Prasad filed a Form 144 notice of proposed sale of 79,393 common shares on November 6, 2026, with an aggregate market value of $3,960,183.20, to be executed through Morgan Stanley Smith Barney LLC.